Recent News

• 02.06.2026 - Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
• 01.23.2026 - Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
• 12.11.2025 - Immunovant Announces Pricing of $550 Million Common Stock Financing

Recent Filings

• 02.06.2026 - EX-99.1 EX-99.1
• 02.06.2026 - 8-K Current report
• 02.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 01.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 8-K Current report
• 12.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 424B5 Prospectus [Rule 424(b)(5)]